NA
BCRX icon

Navellier & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Navellier & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,286
Closed -$431K – 333
2026
Q1 		$431K Buy
45,286
+23,383
+107% +$182K 0.04% 234
2025
Q4 		$171K Sell
21,903
-44,967
-67% -$325K 0.02% 320
2025
Q3 		$508K Buy
66,870
+44,047
+193% +$367K 0.05% 257
2025
Q2 		$204K Buy
+22,823
New +$213K 0.03% 299

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Navellier & Associates's BCRX Position: Q2 2026 in Review

Navellier & Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 45,286 shares — an estimated $431K sold.

Navellier & Associates first reported a position in BCRX in Q2 2025 and held it in 4 quarters. The position peaked at $508K in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Navellier & Associates reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Navellier & Associates sold 45,286 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $431K.
  • Navellier & Associates first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Navellier & Associates's BioCryst Pharmaceuticals position peaked at $508K in Q3 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.